Illumina's Q3 Revenue Surges 82 Percent on Strong Product Sales, Though Profit Slides

Oct 24, 2007

NEW YORK (GenomeWeb News) — Illumina yesterday said third-quarter revenues bolted 82 percent and R&D spending rose 160 percent, though profits fell 10 percent.

Total receipts for the three months ended Sept. 30 increased to $97.5 million from $53.5 million year over year.

Product revenues leapt to $90 million from $46.9 million, while service and other revenue rose to $7.4 million from $6.4 million year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

DNA Defense Not Convincing

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Keep on Brushing

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Panda Gut Seasonality

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

This Week in PLOS

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.

Main menu